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Abstract: 
Introduction 
HCRN LUN 14-179 is a phase II trial of consolidation pembrolizumab following 
concurrent chemoradiation for the treatment of patients with stage III NSCLC.  Time to 
metastatic disease, progression free survival and overall survival appear superior to historical 
controls of chemoradiation alone.  Unfortunately, not all patients benefit from consolidation 
immunotherapy.  We performed a univariate analysis evaluating variables associated with PFS, 
metastatic disease, and OS.    
Methods 
We conducted a retrospective analysis from patients enrolled on HCRN LUN14-179. 
Data collected included age, sex, stage, smoking status, PD-L1 status, >G2 vs <G1 adverse 
event, <G2 vs. >G3 pneumonitis, duration of pembrolizumab (<4 vs. >4 cycles), chemotherapy 
regimen, PS 0 vs 1, time to start pembrolizumab (4-6 vs. 6-8 weeks from radiation), V20 (<20% 
vs. >20%). Univariable Cox regression was performed to determine the variables associated with 
3 endpoints: TMDD; PFS; and OS.   
Results 
From April 2015 to December 2016, 93 patients were enrolled and 92 were included in 
the efficacy analysis (1 patient was ineligible). For TMDD, improved outcomes may be 
associated (p<0.1) with stage IIIA, non-squamous cell, >4 cycles of pembrolizumab, and V20< 
20%.  For PFS, improved outcomes (p<0.1) may be seen for >4 cycles of pembrolizumab, and 
V20< 20%. For OS, improved outcomes (p<0.1) may be seen for non-squamous histology, >4 
cycles of pembrolizumab.   
Conclusion 
Non-squamous NSCLC, longer duration of pembrolizumab, and V20< 20% may be 
associated with prolonged time to metastatic disease or death, PFS, and OS for patients with 
stage III NSCLC treated with chemoradiation followed by pembrolizumab.   
Keywords: 
Immunotherapy, Non-small cell lung cancer, Adjuvant therapy, Prognosis. 
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Introduction: 
Over the last 20 years, the 5 year survival rate for patients with stage IIIA and IIIB 
NSCLC has been 10-15% and 3-7%, respectively1. The standard of care for these patients during 
this period remained concurrent chemotherapy and radiation therapy2-4.  This standard has 
recently changed, based upon the results from the randomized, phase III PACIFIC trial.  In this 
study, patients with stage III NSCLC were treated with a variety of chemotherapy regimens 
concomitantly with radiation therapy and subsequently randomized in a 2:1 fashion to receive 
either durvalumab, a PD-L1 inhibitor, or placebo for up to 1 year.   Median progression-free 
survival for those receiving durvalumab was 16.8 compared with 5.6 months for placebo.  
Overall survival was also improved for those receiving durvalumab with a 24-month overall 
survival rate of 66.3% compared with 55.6% in the placebo group5.  A phase II study from the 
Hoosier Cancer Research Network (HCRN LUN 14-179) evaluated the role of consolidation 
pembrolizumab after chemoradiation in patients with stage III NSCLC. This study recruited 
patient from 14 sites in the U.S.   Results from this study indicated efficacy outcomes 
[progression free-survival (PFS), time to metastatic disease or death (TMDD), and overall 
survival (OS)] similar to those achieved with durvalumab in the PACIFIC trial with median 
TMDD of 22.4 months and a median PFS of 17 months in a similar study population. 
Prognostic variables associated with improved outcomes in patients with stage III 
NSCLC treated with chemoradiation are well characterized.  Performance status 0-1, absence of 
weight loss in the 3 months preceding the diagnosis of lung cancer, stage IIIA (compared with 
IIIB) disease, and volume of lung receiving at least 20 Gy of radiation (V20) < 20% are 
associated with improved outcomes6-8.  However, prognostic variables associated with improved 
efficacy from consolidation immunotherapy after chemoradiation therapy have not been defined.  
The anti-cancer mechanisms of checkpoint inhibitors is substantially different than conventional 
chemotherapy.  Furthermore, checkpoint inhibitors are associated with a vastly different side 
effect profile compared with conventional chemotherapy.  We, therefore, performed this 
retrospective subset analysis to evaluate potential prognostic variables associated with 
improvements in TMDD, PFS, and OS in patients with stage III NSCLC treated with 
chemoradiation followed by pembrolizumab from the HCRN LUN 14-179 clinical trial.   
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Methods: 
Study population 
We conducted a retrospective analysis from patients enrolled on HCRN LUN 14-179.  
This was a single arm, phase II trial of concurrent chemoradiation followed by consolidation 
pembrolizumab 200 mg IV every 3 weeks until disease progression, unacceptable toxicity, or up 
to 1 year of therapy was completed.  Patients were permitted to receive carboplatin plus 
paclitaxel, cisplatin plus etoposide, or cisplatin plus pemetrexed (non-squamous cell only) given 
concurrently with 59.4-66.6 Gy XRT.  Patients were also permitted up to 2 cycles of 
consolidation chemotherapy.  Patients with non-progression of disease were then enrolled onto 
the clinical trial.  Eligible patients had a PS of 0-1, stage IIIA or IIIB squamous or non-squamous 
NSCLC.  Patients with contraindications to checkpoint inhibitors were excluded, including a 
history of non-infectious pneumonitis or interstitial lung disease.  Patients were not excluded 
based upon pulmonary function, V20 or weight loss.  The primary objective of the overall study 
was to determine if consolidation pembrolizumab following concurrent chemoradiation improves 
time to death or metastatic disease in inoperable stage III NSCLC patients.  The efficacy and 
safety results of the overall study population have been reported9. The primary objective of this 
subset analysis was to determine prognostic variables associated with TMDD, PFS and OS.   
Prognostic variables 
Prognostic variables considered for this analysis included age, sex, stage of NSCLC (IIIA 
vs. IIIB), histology (squamous vs. non-squamous), smoking status (current vs. former vs. never 
smoker), PD-L1 status (>1% vs. < 1%), any adverse event grade ((≤ G2 vs. ≥ G3), pneumonitis 
(≤ G2 vs. ≥ G3), duration of treatment with pembrolizumab (< 4 vs. ≥ 4 cycles), chemotherapy 
regimen (carboplatin/paclitaxel vs. cisplatin/etoposide), ECOG performance status (0 vs. 1), 
interval between completion of radiation to start of pembrolizumab (4-6 weeks vs. 6-8 weeks) 
and volume of lung receiving at least 20 Gy of radiation (V20) (≤ 20% vs. >20%).   PD-L1 
testing was performed using modified proportion score (MPS).  This scoring system includes 
both PD-L1 positive mononuclear inflammatory cells (MIC), including macrophages and 
lymphocytes, and tumor cells.  It also evaluates MICs within the tumor-associated stroma, 
though this is not factored into the percent MPS score. 
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Statistical analysis 
Data analysis was conducted using SAS software version 9.4 (SAS Institute Inc., Cary, 
NC). A p-value < .05 denoted statistical significance for all tests. Basic comparisons were made 
using Chi-Square Tests. Univariable Cox regression was performed to determine the variables 
associated with 3 endpoints: TMDD, PFS and OS. Variables found to have a P < 0.1 on 
univariable Cox regression analysis were included in a multivariable Cox regression model.  Due 
to a small sample size (n=92), we chose p < 0.1 as the cutoff in the univariable regression for 
inclusion into the multivariable regression model, to allow us to still develop hypothesis-
generating prognostic variables to be studied in larger trials in the future.. 
Results: 
From April 2015 to December 2016, 93 patients were enrolled and 92 were included in 
the efficacy analysis (1 patient was ineligible). The median follow-up was 30.5 months with a 
minimum follow-up of 26 months for patients who are alive.  Patient and disease characteristics 
are summarized in Table 1.  
For time to metastatic disease or death (TMDD), improved outcomes (p<0.1) were 
associated with stage IIIA (p=0.0922), non-squamous cell (p=0.0999), > 4 cycles of 
pembrolizumab (p<0.001), and V20 ≤ 20% (p=0.0716) according to the Univariable Cox 
regression model. A multivariable model was run with those variables and Stage IIIA (HR=2.9, 
p=0.02) and >4 cycles of pembrolizumab (HR=9.1, p<0.001) remained significant. On the other 
hand, smoking status was not associated with a difference in TMDD (p=0.7204) on univariable 
Cox regression model. PDL-1 status was also not associated with TMDD (p=0.3505) (Table 3). 
For PFS, improved outcomes (p<0.1) may be seen for >4 cycles of pembrolizumab 
(p<0.001), and V20≤ 20% (p=0.0630) according to the Univariable Cox regression model. A 
multivariable model was run with those variables and >4 cycles of pembrolizumab (HR=3.9, 
p<0.001) remained significant. Smoking status (p=0.9679), PDL-1 status (p=0.3261), and stage 
IIIA vs. IIIB (p=0.1444) were not associated with PFS. (Table 4). 
For OS, improved outcomes (p<0.1) may be seen for non-squamous histology 
(p=0.0829), and > 4 cycles of pembrolizumab (p<0.001) according to the univariable Cox 
regression model. A multivariable model was run with those variables and > 4 cycles of 
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pembrolizumab (HR=4.9, p<0.001) remained significant. Smoking status (p=0.6043), PDL-1 
status (p=0.1901) and stage of disease (p=0.1588) were not prognostic for OS (Table 5).  
 
Table 1: Baseline characteristics of study population (N=92) 
Characteristics Statistics 
Age (years), mean (std) 64 (8.6) 
Gender, n (%) 
 
Male 59 (64) 
Female 33 (36) 
Stage, n (%) 
 
IIIA 55 (60) 
IIIB 37 (40) 
Histology of NSCLC, n (%) 
 
Non-squamous 51 (55) 
Squamous 41 (45) 
Distant metastasis or death on follow-up*, n 
(%) 
 
Present 34 (37) 
Not present 57 (63) 
*One patient did not have an evaluable response for distant metastasis or death 
 
Table 2: Basic comparisons of outcomes 
Variable TMDD PFS OS 
IIIA (n=55) 
IIIB (n=37) 
69%   p=0.12 
51% 
56%   p=0.21 
41% 
75%  p=0.13 
59% 
Non-SCCA (n=51) 
SCCA (n=41) 
69%   p=0.11 
54% 
55%   p=0.21 
44% 
75%   p=0.16 
61% 
PD-L1 [-] (n=11) 
PD-L1 [+] (n=42) 
82%   p=0.13 
57% 
64%   p=0.19 
40%  
91%   p=0.07 
62% 
Downloaded for Anonymous User (n/a) at Indiana University Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on July 15, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
> 4 pembro (n=77) 
< 4 pembro (n=15) 
68%   p=0.01 
33% 
55%   p=0.04 
27% 
75%   p=0.001 
33% 
V20 ≤ 20% (n=19) 
V20 > 20% (n=59) 
79%   p=0.07 
54% 
63%    p=0.08 
39% 
79%   p=0.15 
61% 
G < 2 pneumonitis (n=87) 
G > 3 pneumonitis (n=5) 
63%   p=0.28 
40% 
51%   p=0.61 
40% 
70%   p=0.16 
40% 
Female (n=33) 
Male (n=59) 
67%   p=0.37 
59% 
67%   p=0.11 
59% 
73%   p=0.51 
66% 
<65 years old (n=43) 
≥65 years old (n=49) 
56%   p=0.32 
67% 
49%   p=0.99 
51% 
65%   p=0.52 
71% 
Current Smoker (n=16) 
Former Smoker (n=71) 
Never Smoker (n=5) 
50%   p=0.42 
66% 
40% 
50%   p=0.99 
51% 
40% 
56%   p=0.44 
72% 
60% 
Any AE Grade ≤2 (n=46) 
Any AE Grade ≥3 (n=46) 
70%   p=0.17 
54% 
56%   p=0.29 
43% 
76%   p=0.12 
61% 
Carboplatin/Paclitaxel (n=66) 
Cisplatin/Etoposide (n=24) 
59%   p=0.57 
67% 
44%   p=0.15 
63% 
65%   p=0.38 
75% 
Rad Interval 4-6 weeks (n=17) 
Rad Interval 6-8 weeks (n=75) 
53%   p=0.56 
64% 
41%   p=0.71 
52% 
59%   p=0.34 
71% 
ECOG=0 (n=40) 
ECOG=1 (n=52) 
68%   p=0.40 
58% 
55%   p=0.38 
46% 
73%   p=0.47 
65% 
 
Table 3: Univariate analysis for prognostic variables associated with time to metastatic 
disease or death 
  Univariable Results Multivariable Results 
Variable Comparison* 
Hazard Ratio 
(95% CI) p-value 
 
Hazard Ratio 
(95% CI) 
 
p-value 
Age <65 vs. ≥65 years old 1.00 (0.96, 1.04) 0.9678   
Gender Female vs Male 0.97 (0.46, 2.04) 0.9401   
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  Univariable Results Multivariable Results 
Variable Comparison* 
Hazard Ratio 
(95% CI) p-value 
 
Hazard Ratio 
(95% CI) 
 
p-value 
Stage IIIB vs IIIA 1.79 (0.91, 3.52) 0.0922 2.87 (1.21, 6.81) 0.0165 
Histology non-squamous vs 
squamous 
0.57 (0.29, 1.12) 0.0999 0.63 (0.30, 1.32) 0.2192 
Smoking status Current vs Former 1.39 (0.62, 3.10) 0.7204   
 
Current vs Never 1.21 (0.25, 5.74)    
 
Former vs Never 0.87 (0.20, 3.71)    
PDL-1 status Negative vs Positive 0.50 (0.12, 2.16) 0.3505   
Any adverse 
event 
Grade <=2 vs Grade >=3 0.65 (0.33, 1.29) 0.2194   
Pneumonitis 
grade 
Grade <=2 vs Grade >=3 0.57 (0.17, 1.86) 0.3493   
Duration of 
treatment with 
pembrolizumab 
<4 cycles vs >=4 cycles of 
treatment 
5.98 (2.75, 13.00) <.0001 9.14 (3.35, 24.92) <.0001 
Type of chemo Carboplatin/Paclitaxel vs 
Cisplatin/Etoposide 
1.36 (0.61, 3.03) 0.4462   
ECOG 0 vs 1 0.63 (0.31, 1.29) 0.2035   
Time between 
radiation to 
pembrolizumab 
4-6 weeks vs 6-8 weeks 1.40 (0.61, 3.24) 0.4315   
V20 <=20% vs >20% 0.38 (0.13, 1.09) 0.0716 0.64 (0.21, 1.95) 0.4346 
*reference category is the second category 
Table 4: Univariate analysis for prognostic variables associated with progression-free 
survival 
  Univariable Results Multivariable Results 
Variable Comparison* 
Hazard Ratio 
(95% CI) p-value 
 
Hazard Ratio 
(95% CI) 
 
p-value 
Age <65 vs. ≥65 years old 1.00 (0.97, 1.04) 0.8557   
Gender Female vs Male 0.80 (0.41, 1.55) 0.5065   
Stage IIIB vs IIIA 1.56 (0.86, 2.83) 0.1444   
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  Univariable Results Multivariable Results 
Variable Comparison* 
Hazard Ratio 
(95% CI) p-value 
 
Hazard Ratio 
(95% CI) 
 
p-value 
Histology non-squamous vs 
squamous 
0.72 (0.41, 1.31) 0.2859   
Smoking status Current vs Former 1.04 (0.48, 2.25) 0.9679   
 
Current vs Never 1.22 (0.26, 5.80)    
 
Former vs Never 1.18 (0.28, 4.93)    
PDL-1 status Negative vs Positive 0.59 (0.20, 1.70) 0.3261   
Any adverse 
event 
Grade <=2 vs Grade >=3 0.78 (0.43, 1.41) 0.4031   
Pneumonitis 
grade 
Grade <=2 vs Grade >=3 0.83 (0.26, 2.67) 0.7472   
Duration of 
treatment with 
pembrolizumab 
<4 cycles vs >=4 cycles of 
treatment 
4.25 (2.11, 8.59) <.0001 3.87 (1.82, 8.25) 0.0005 
Type of chemo Carboplatin/Paclitaxel vs 
Cisplatin/Etoposide 
1.65 (0.79, 3.44) 0.1839   
ECOG 0 vs 1 0.71 (0.38, 1.30) 0.2665   
Time between 
radiation to 
pembrolizumab 
4-6 weeks vs 6-8 weeks 1.44 (0.66, 3.11) 0.3599   
V20 <=20% vs >20% 0.46 (0.20, 1.04) 0.0630 0.57 (0.25, 1.33) 0.1929 
*reference category is the second category 
Table 5: Univariate analysis for prognostic variables associated with overall survival 
  Univariable Results Multivariable Results 
Variable Comparison* 
Hazard Ratio 
(95% CI) p-value 
 
Hazard Ratio 
(95% CI) 
 
p-value 
Age <65 vs. ≥65 years old 1.01 (0.96, 1.05) 0.7975   
Gender Female vs Male 0.84 (0.38, 1.85) 0.6634   
Stage IIIB vs IIIA 1.69 (0.81, 3.52) 0.1588   
Histology non-squamous vs squamous 0.52 (0.25, 1.09) 0.0829 0.64 (0.30, 1.35) 0.2390 
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  Univariable Results Multivariable Results 
Variable Comparison* 
Hazard Ratio 
(95% CI) p-value 
 
Hazard Ratio 
(95% CI) 
 
p-value 
Smoking status Current vs Former 1.55 (0.66, 3.67) 0.6043   
 
Current vs Never 1.48 (0.31, 7.18)    
 
Former vs Never 0.95 (0.22, 4.11)    
PDL-1 status Negative vs Positive 0.26 (0.03, 1.96) 0.1901   
Any adverse 
event 
Grade <=2 vs Grade >=3 0.55 (0.26, 1.17) 0.1208   
Pneumonitis 
grade 
Grade <=2 vs Grade >=3 0.37 (0.11, 1.23) 0.1034   
Duration of 
treatment with 
pembrolizumab 
<4 cycles vs >=4 cycles of 
treatment 
5.40 (2.43, 12.02) <.0001 4.91 (2.18, 11.06) 0.0001 
Type of chemo Carboplatin/Paclitaxel vs 
Cisplatin/Etoposide 
1.58 (0.64, 3.90) 0.3225   
ECOG 0 vs 1 0.71 (0.33, 1.54) 0.3862   
Time between 
radiation to 
pembrolizumab 
4-6 weeks vs 6-8 weeks 1.54 (0.65, 3.63) 0.3225   
V20 <=20% vs >20% 0.51 (0.17, 1.48) 0.2136   
*reference category is the second categor 
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Discussion: 
Prognostic variables associated with better or worse outcomes for patients with stage III 
NSCLC treated with concurrent chemoradiation are well characterized7.  However, prognostic 
variables associated with outcomes are not well defined in this patient population receiving 
consolidation PD-1 or PD-L1 inhibition. The analysis performed from HCRN LUN 14-179 
reported here indicates that receiving 4 or more cycles of consolidation pembrolizumab is 
associated with improved PFS, TMDD, and OS compared with receiving fewer than 4 cycles. 
The interpretation of this, however, should be undertaken with caution.  It is possible (and even 
likely) that this simply represents a patient population who tolerated therapy well and may have 
had more favorable tumor biology.  It should be noted, though, that duration of pembrolizumab 
therapy remained prognostic when factoring in other variables, including stage, PD-L1 score, 
histology, V20, and PS, which can influence efficacy outcomes.   The optimal duration of 
consolidation PD-1 or PD-L1 inhibition after chemoradiation is not defined.  The PACIFIC trial 
and the HCRN LUN 14-179 trials each permitted up to 1 year of consolidation checkpoint 
inhibition.  Approximately 40% of patients on each study were able to receive 1 year of therapy, 
and the median duration of consolidation therapy received in both studies was approximately 9 
months5.   
Other known prognostic variables for patients with stage III NSCLC were evaluated in 
the current study.  V20 < 20% is associated with less toxicity and better outcomes for patients 
treated with chemoradiation for stage III NSCLC10.  Based upon the current analysis, it appears 
that V20 < 20% is also associated with improved PFS and TMDD with consolidation 
pembrolizumab. Lower V20 may simply be a surrogate for lower volume of disease, selecting 
out patients who may be more curable.   Furthermore, non-squamous NSCLC was also 
associated with improved survival with consolidation pembrolizumab.   
Subset analyses from the PACIFIC trial suggested that patients with PD-L1 expression of 
< 1% may not have improved survival with consolidation durvalumab compared with placebo, 
although PFS was improved with durvalumab in that  analysis5.  The HCRN LUN 14-179 trial 
utilized a PD-L1 testing platform that assessed PD-L1 expression in tumor cells along with other 
cells in the microenvironment.  Utilizing this assay, PD-L1 expression of < 1% was not 
associated with inferior survival with consolidation pembrolizumab. It is possible that the 
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utilization of different assays resulted in disparate results between HCRN LUN 14-179 and the 
PACIFIC trial.  The optimal therapy for patients with PD-L1 scores of 1% remains undefined. 
In addition, a subset analysis from the PACIFIC trial suggested that initiating 
consolidation durvalumab within 2 weeks of completing chemoradiation was associated with 
improved outcomes5.  In contrast, patients enrolled onto HCRN LUN 14-179 were required to 
wait a minimum of 4 weeks and a maximum of 8 weeks after completing chemoradiation prior to 
initiating pembrolizumab.  The current study evaluated the differences in outcomes of patients 
initiating pembrolizumab 4-6 weeks after chemoradiation versus those initiating pembrolizumab 
6-8 weeks after chemoradiation.  No difference was detected in efficacy outcomes (PFS, TMDD, 
OS) between these subgroups.  It is possible that patients receiving durvalumab within 2 weeks 
of chemoradiation on the PACIFIC trial represented patients with fewer medical problems, 
improved tolerance to therapy, and better performance status.  Furthermore, smoking status, age, 
gender, chemotherapy regimen, and development of pneumonitis during consolidation 
immunotherapy do not appear to be associated with outcomes in this patient population.   
While this was the first attempt to evaluate prognostic variables utilizing immunotherapy 
after chemoradiation for patients with stage III NSCLC, it is important to recognize the 
limitations of this analysis.  This analysis was retrospective and unplanned.  Secondly, a p value 
of <1% was utilized as a cut-off for utilization in the multivariate model.  Third, the sample size 
of this study is relatively small.  Fourth, the PD-L1 assay utilized is not standard.  Fifth, PFS can 
be challenging to define in a patient population treated with radiation due to the difficulty of 
interpreting local progression.  Nevertheless, despite these significant limitations, this study 
serves as hypothesis generating to test variables in larger studies of this patient population..  
In conclusion, this is the first dedicated report assessing prognostic variables associated 
with outcomes in patients with stage III NSCLC treated with chemoradiation followed by 
consolidation pembrolizumab.  Efforts are underway to build off the success of the PACIFIC and 
HCRN LUN 14-179 trials.  Given the increased risks and costs associated with consolidation 
immunotherapy in this setting, it is essential to define the optimal duration of immunotherapy 
and to identify prognostic markers associated with benefit (or detriment) with this strategy.  One 
such effort is underway through the BIG10 Cancer Research Consortium (NCT03285321) which 
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will evaluate multiple clinical factors, radiation treatment variables, and molecular biomarkers 
associated with outcomes in patients treated with consolidation immunotherapy strategies. 
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